Medscape1d
Fidaxomicin: A New Macrocyclic, RNA Polymerase-inhibiting Antibiotic for the Treatment of Clostridium difficile Infections
Mild Clostridium difficile infection (CDI; stool frequency <four-times daily; no signs of severe colitis), clearly induced by the use of antibiotics ... recent trials show fidaxomicin to have ...
Clostridium Difficile Infection Treatment Market Size Worth US$ 2.28 Billion by 2034 at a CAGR Of 6.3% | Fact.MR Report
Pharmaceutical Innovations, Collaborative Research Initiatives, and Increased Awareness Driving Clostridium Difficile Infection Treatment Market GrowthRockville, MD, Jan. 23, 2025 (GLOBE NEWSWIRE) -- ...